Compare TPH & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPH | IOVA |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | 975 |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 1.7B |
| IPO Year | 2012 | 2008 |
| Metric | TPH | IOVA |
|---|---|---|
| Price | $46.36 | $3.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $42.50 | $9.11 |
| AVG Volume (30 Days) | 3.3M | ★ 17.2M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $3,260,447,000.00 | N/A |
| Revenue This Year | N/A | $49.14 |
| Revenue Next Year | $10.55 | $51.69 |
| P/E Ratio | $17.04 | ★ N/A |
| Revenue Growth | ★ 5.76 | N/A |
| 52 Week Low | $27.90 | $1.64 |
| 52 Week High | $46.62 | $5.63 |
| Indicator | TPH | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 80.96 | 52.02 |
| Support Level | $46.26 | $1.99 |
| Resistance Level | $46.61 | $4.34 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | -0.45 | -0.08 |
| Stochastic Oscillator | 38.16 | 18.54 |
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. Its financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.